Meenakshi Rana, MD
Infectious Disease · New York, NYNPI 1619099850
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,788 of the $2,078 with a category attached, or 86.0%. Lilly USA, LLC accounts for 86.0% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $1,835 and has fallen 96.5% since, to $63 in 2023.
Across 14 payments — averaging $148.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Daiichi Sankyo Inc.$101
- GSK$73
- Genentech USA, Inc.$68
- Cumberland Pharmaceuticals, Inc.$21
- Merck$15
- plus $12 from 1 others
Across 75 payments — averaging $3298.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$130K
- Pfizer$69K
- Regeneron$49K
What the payments were for
- Consulting fees$1,78886%
- Food & beverage$29114%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 2 | $1,788 |
| Daiichi Sankyo Inc. | 1 | $101 |
| GSK | 5 | $73 |
| Genentech USA, Inc. | 3 | $68 |
| Cumberland Pharmaceuticals, Inc. | 1 | $21 |
| Merck | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INJECTAFER$101
How this compares
$2,078 in reported general payments places this provider in the 80th percentile of 799 infectious disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 18 | $68,341 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 32 | $296 |
| Isoniazid | 23 | $94 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in New York
- Sian JonesNew York$406K
- Antonio UrbinaNew York$373K
- David BekhorNew York$358K
- Genovefa PapanicolaouNew York$209K
- Michelle CespedesNew York$125K
- Donald KaminskyNew York$120K
- Judith AbergNew York$104K
- Thomas WalshNew York$98K
- Stuart HaberNew York$73K
- Michael GaisaNew York$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.